Home > Healthcare > Pharmaceuticals > Finished Drug Form > Infectious Enteritis Treatment Market

Infectious Enteritis Treatment Market Share

Report ID: GMI9216
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Infectious Enteritis Treatment Market Share

The infectious enteritis treatment industry hosts numerous companies competing for market share. Key players dominate with their comprehensive treatment offerings for gastrointestinal disorders such as IBS and enteritis. These companies compete through product innovation, regulatory approvals, and strategic partnerships to capture market share and address the diverse needs of patients and healthcare providers.

Infectious Enteritis Treatment Market Companies

Some of the prominent players operating in the infectious enteritis treatment industry include:

Abbott Laboratories
Almirall SA
AstraZeneca PLC
Bristol-Myers Squibb
F. Hoffmann-La Roche Ltd
GSK plc
Medimetriks Pharmaceuticals Inc.
Merck KGaA
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Zydus Lifesciences Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The infectious enteritis treatment market size was valued at USD 434.8 million in 2023 and will grow at 6.3% CAGR from 2024 to 2032, propelled by the rising incidence of infectious diseases globally.

Infectious enteritis treatment industry from the antibiotics drug type segment will reach USD 388.5 million by end of 2032, owing to its ability to effectively target various enteric infections in adults.

U.S. infectious enteritis treatment market size was 167.9 million in 2023 and will show significant growth over the analysis period, driven by favorable regulatory frameworks, coupled with the introduction of advanced products.

Abbott Laboratories, Almirall SA, AstraZeneca PLC, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, GSK plc, Medimetriks Pharmaceuticals Inc., Merck KGaA, and Pfizer Inc. among others.